Skip to content

Risk and Incidence of Aortic Graft and Endograft Infection With BSI

Risk and Incidence of Aortic Graft and Endograft Infection in Patients With Bloodstream Infection, a Population Based Study in South Sweden

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05521035
Enrollment
2000
Registered
2022-08-30
Start date
2022-09-01
Completion date
2024-09-01
Last updated
2023-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Infections and Inflammations

Brief summary

What is the risk of aortic vascular graft and endograft infection in patients with aortic vascular graft/endograft and bloodstream infection?

Detailed description

All patients with previous aortic vascular graft and endograft surgery between years 2010 and 2021 in four regions of south Sweden (Skåne, Halland, Kronoberg and Blekinge) will be included in the study. These patients will be evaluated for bloodstream infection (BSI) or not. For all patients with BSI, the risk of aortic vascular graft and endograft infection will be investigated. Aortic vascular graft and endograft infection will be determined by usage of the MAGIC-criteria. Risk factors for developing aortic vascular graft and endograft infection will be investigated, and if possible used to construct a risk score. This risk score could be used by clinicians to determine if bacteremic patients with aortic vascular grafts or endografts should be evaluated for aortic vascular graft and endograft infection.

Interventions

None listed

Sponsors

Lund University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Previous aortic vascular graft or endograft infection with bloodstream infection.

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Aortic vascular graft or endograft infectionAt least 1 year follow-upDetermined by the MAGIC-criteria

Countries

Sweden

Contacts

Primary ContactOskar Ljungquist, M.D, PhD
oskar.ljungquist@med.lu.se+46424061000
Backup ContactTorgny Sunnerhagen, M.D, PhD
torgny.sunnerhagen@med.lu.se

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026